Faster Launch, Increased Adoption, Higher Revenue, and a Playbook for Commercial Success. Read the white paper.
Download Now
Skip to content
prognos-logo-light Prognos Health
Main Menu
  • Support
  • Client Login
  • Request Demo
  • Prognos Factor®
    • Marketplace
      • Explore & Buy Data
      • Become a Data Provider
  • Products
    • Life Sciences
      • Cohort Designer
      • Patient Journey Software
      • Physician Segmentation
      • Outcomes Insights
      • Alerts
      • Omnichannel Marketing
    • Payers
      • Underwriting Risk Predictor
  • Company
    • Careers
    • News
    • Insights
    • Resources
  • Contact Us
Home Insights What to Consider if Your Drug is a Targeted Therapy for a New Biomarker

What to Consider if Your Drug is a Targeted Therapy for a New Biomarker

  • April 4, 2019
  • Posted in Lab Testing Insights

This post was last updated on December 29, 2020 at 1:41 pm

Biomarker vials

A Follow Up to “Biomarker Testing in Non-Small Cell Lung Cancer“

By Melissa Leonhauser, General Manager, Alert & Targeting Portfolio

More and more targeted cancer therapies are being developed. But, after approval, the brand team faces an uphill battle in getting physicians to test for any new biomarkers the drugs are intended to treat. As my colleague Bill explained in his blog on NSCLC testing, physicians are much less likely to test for biomarkers that are new or don’t have one or two approved targeted therapies.

Bill analyzed testing of non-small cell lung cancer patients and found that PD-L1 is the most widely tested for mutation with EGFR mutation and ALK gene rearrangement testing following.  Each of these biomarkers has had targeted therapies approved and on the market for years. Newer biomarkers such as ROS1, are tested for at a lower rate. In 2018, 85% of NSCLC patients were tested for PD-L1 expression but only 49% were tested for ROS1 gene rearrangement.

With this knowledge, brand teams for drugs targeted at new or newer biomarkers should prepare a strategy to positively influence physicians to increase testing for that biomarker.  Afterall, physicians aren’t likely to treat with the drug if it isn’t discovered that the patient has the gene mutation or expression the drug targets. More tests = more eligible patients found.

The brand team should set a reasonable expectation for how much testing is likely to occur in the first year or first 6 months after launch by looking at the uptake of testing for other biomarkers, similar to how they may have used a drug analog to forecast launch performance.  For instance, if the drug launching treats non-small cell lung cancer, they could look at trends in ROS1 testing and the launch of Xalkori.

In addition, brand teams can look at which physicians were early adopters of other new biomarker tests.  It’s likely that these physicians would be the first to test for their targeted biomarker as well. A physician who typically treats patients with the malignancy AND is an early adopter of new testing, should surely be educated on their treatment early on and often.

« Available Omnichannel HCP Data Sources
Deterministic or predictive profiles? How to optimize your HCP promotional activities across channels »

Categories

  • AI
  • Alerts
  • Clinical
  • Commercial Launch Excellence
  • Disease Awareness
  • Lab Testing Insights
  • Lab Testing Trends
  • Marketplace
  • Omnichannel Marketing
  • Patient Journey
  • Physician Segmentation
  • Prog Spotlight
  • RWD
  • Technology
  • Underwriting

Archives

Latest Tweets

Prognos HealthFollow

Query billions of fully-integrated lab & health records on more than 325M de-identified patients to answer key healthcare questions in minutes on prognosFACTOR.

Prognos Health
prognosAIPrognos Health@prognosAI·
12 Apr

In our recent panel discussion “How to determine your next best action for every HCP engagement”, leaders from Novartis, GSK, and Takeda Oncology discussed their #RWD strategies to commercialize drug therapies. 3 important best practices were revealed. https://prognoshealth.com/blog/provider-engagement/?utm_source=twitter&utm_medium=social&utm_campaign=provider_engagement_blog

Reply on Twitter 1513876896056057856Retweet on Twitter 1513876896056057856Like on Twitter 1513876896056057856Twitter 1513876896056057856
prognosAIPrognos Health@prognosAI·
7 Apr

68% of #pharma leaders believe the way #lifescience companies currently purchase patient-level data is ripe for disruption.

Find out what challenges dominate current #RWD efforts and how technology can help address them.

https://prognoshealth.com/blog/real-world-data-pharma-paradigm-shift/?utm_source=twitter&utm_medium=social&utm_campaign=rwd_paradigm_shift_blog

#RealWorldData

Reply on Twitter 1512114401360461827Retweet on Twitter 15121144013604618271Like on Twitter 1512114401360461827Twitter 1512114401360461827
prognosAIPrognos Health@prognosAI·
5 Apr

Therapy-related #RWD insights and learnings for a new brand launch can take 12-18 months. One leading #pharma company cut this time in half. Find out how.
https://prognoshealth.com/resource/rwd-analysis/?utm_source=twitter&utm_medium=social&utm_campaign=oncology_case_study

#Omnichannel #Oncology #Pharmaceutical #TherapyLaunch #RealWorldData

Reply on Twitter 1511355425660325897Retweet on Twitter 15113554256603258971Like on Twitter 15113554256603258971Twitter 1511355425660325897
prognosAIPrognos Health@prognosAI·
3 Mar

In a recent survey of #pharma leaders by Reuters, 68% of respondents believe the way #LifeSciences companies currently purchase patient-level data is ripe for disruption.

Find out what challenges dominate current #RWD efforts and how technology can help.

https://prognoshealth.com/blog/real-world-data-pharma-paradigm-shift/?utm_source=twitter&utm_medium=social&utm_campaign=real_world_data_in_pharma_paradigm_shift

Reply on Twitter 1499488030222168066Retweet on Twitter 14994880302221680661Like on Twitter 1499488030222168066Twitter 1499488030222168066
prognosAIPrognos Health@prognosAI·
1 Mar

Dr. Steven Zatz Joins Prognos Health Board of Directors

"Steve’s vision and leadership helped build WebMD into an iconic healthcare brand," says @sundeepbhan1.

https://prognoshealth.com/about-us/news/press-release/dr-steven-zatz-joins-prognos-health-board-of-directors/?utm_source=twitter&utm_medium=social&utm_campaign=dr_zatz_joins_board

Reply on Twitter 1498679196536737795Retweet on Twitter 14986791965367377951Like on Twitter 14986791965367377951Twitter 1498679196536737795
Load More...
  • Prognos Factor®
    • Prognos Marketplace
  • Products
    • Life Sciences
    • Payers
  • Company
    • Insights
    • Careers
    • News
  • LinkedIn
  • Twitter
  • YouTube
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Site Map
© Prognos Health, 2022. All Rights Reserved.

Get Answers Faster

Watch your questions answered with unparalleled speed. De-identified record level patient data already integrated & easily linked to other sources. Prognos puts you in control.

To give you the best possible experience, this site uses cookies and by continuing to use the site you agree that we can save them on your device. For more details about cookies and their use, please see our Privacy Policy.